Literature DB >> 29194943

Understanding of hypertension and heart failure in patients with type 2 diabetes by studying effects of sodium-glucose cotransporter 2 inhibitors on plasma B-type natriuretic peptide levels.

Hidekatsu Yanai1, Hiroki Adachi1, Mariko Hakoshima1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29194943      PMCID： PMC8030913          DOI： 10.1111/jch.13174

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  5 in total

1.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 2.  Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Authors:  S A Jabbour; B J Goldstein
Journal:  Int J Clin Pract       Date:  2008-08       Impact factor: 2.503

3.  Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry.

Authors:  Thomas Mengden; Uwe Ligges; Johanna Mielke; Peter Bramlage; Andrea Korzinek; Walter Sehnert
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-11       Impact factor: 3.738

4.  The role of increased glucose on neurovascular dysfunction in patients with the metabolic syndrome.

Authors:  Sara Rodrigues; Felipe X Cepeda; Edgar Toschi-Dias; Akothirene C B Dutra-Marques; Jefferson C Carvalho; Valéria Costa-Hong; Maria Janieire N N Alves; Maria Urbana P B Rondon; Luiz A Bortolotto; Ivani C Trombetta
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-04       Impact factor: 3.738

Review 5.  Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyama; Hidetaka Hamasaki; Hiroki Adachi; Sumie Moriyama; Reo Yoshikawa; Akahito Sako
Journal:  J Clin Med Res       Date:  2015-12-03
  5 in total
  4 in total

1.  Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes.

Authors:  Hidekatsu Yanai
Journal:  Ann Transl Med       Date:  2017-12

2.  Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.

Authors:  Mariko Hakoshima; Hidekatsu Yanai; Kouki Kakuta; Hiroki Adachi
Journal:  J Clin Med Res       Date:  2018-04-13

Review 3.  Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.

Authors:  Hidekatsu Yanai; Mariko Hakoshima; Hiroki Adachi; Hisayuki Katsuyama
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 4.  Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.

Authors:  James Shaffner; Bohan Chen; Deepak K Malhotra; Lance D Dworkin; Rujun Gong
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-01       Impact factor: 5.555
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.